FDA finalizes guidance on considerations for evaluating drug’s benefits and risks
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesClinical TrialsComplianceHealth Authority meeting and communication strategyNorth AmericaPharmaceuticalsPharmacovigilanceRegulatory Intelligence/Policy